TypeZero/Tandem Diabetes Care/Dexcom: An artificial pancreas with Virginia roots
Last July, Tandem Diabetes Care inked a license agreement with TypeZero Technologies to integrate TypeZero’s artificial pancreas into Tandem’s next-gen t:slim insulin pump.
TypeZero’s artificial pancreas technology includes algorithms developed off of initial research conducted at the University of Virginia, and the company said it has been used in more than 28 clinical studies including more than 475 participants.
The combined technologies include an insulin pump from Tandem, a Dexcom G5 sensor and TypeZero’s inControl hybrid closed loop algorithm.
As part of the agreement, a research version of the t:slim insulin pump will be used alongside TypeZero’s AP tech in the International Diabetes Closed Loop Trial which began in late 2016 and was funded by the National Institute of Health. Financial details of the deal were not disclosed.
In January 2015, a device developed at the University of Virginia School of Medicine which automatically monitors and regulates blood-sugar level in type 1 diabetes patients began undergoing 2 final clinical trials. UVA said it was hopeful that the long-term clinical trials would pave the way for FDA clearance of the artificial pancreas devices for type 1 diabetes sufferers.
The 1st study, the International Diabetes Closed-Loop trial, aimed to test UVA developed technology. The university’s technology has been “further refined for clinical use” by Charlottesville, Va.–based startup TypeZero Technologies, which licensed the technologies.